| Dr Simon Nicholas Fenton, MD | |
|
150 Emerson Ave E, Saint Paul, MN 55118-2535 | |
| (651) 241-1800 | |
| Not Available |
| Full Name | Dr Simon Nicholas Fenton |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 18 Years |
| Location | 150 Emerson Ave E, Saint Paul, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083640684 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 49982 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Abbott Northwestern Hospital | Minneapolis, MN | Hospital |
| Allina United Hospital | Saint paul, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allina Health System | 4587573613 | 3071 |
News Archive
Researchers from the US recently conducted a study to examine the clinical course and echocardiographic and lab testing across clinically defined fulminant and non-fulminant COVID-19 myocarditis. This study is published on the preprint server, medRxiv.*
Rapidly dividing cancer cells are skilled at patching up damage that would stop normal cells in their tracks, including wear and tear of telomeres, the protective caps at the end of each chromosome.
Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.
A new perspective article highlights a compelling theory about migraine attacks: that they are an integrated mechanism by which the brain protects and repairs itself. Recent insightful findings and potential ways to use them to help migraine sufferers are published in Headache.
› Verified 8 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
Researchers from the US recently conducted a study to examine the clinical course and echocardiographic and lab testing across clinically defined fulminant and non-fulminant COVID-19 myocarditis. This study is published on the preprint server, medRxiv.*
Rapidly dividing cancer cells are skilled at patching up damage that would stop normal cells in their tracks, including wear and tear of telomeres, the protective caps at the end of each chromosome.
Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.
A new perspective article highlights a compelling theory about migraine attacks: that they are an integrated mechanism by which the brain protects and repairs itself. Recent insightful findings and potential ways to use them to help migraine sufferers are published in Headache.
› Verified 8 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457657249 PECOS PAC ID: 4587573613 Enrollment ID: O20221213001713 |
News Archive
Researchers from the US recently conducted a study to examine the clinical course and echocardiographic and lab testing across clinically defined fulminant and non-fulminant COVID-19 myocarditis. This study is published on the preprint server, medRxiv.*
Rapidly dividing cancer cells are skilled at patching up damage that would stop normal cells in their tracks, including wear and tear of telomeres, the protective caps at the end of each chromosome.
Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.
A new perspective article highlights a compelling theory about migraine attacks: that they are an integrated mechanism by which the brain protects and repairs itself. Recent insightful findings and potential ways to use them to help migraine sufferers are published in Headache.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Simon Nicholas Fenton, MD Po Box 43, Mr 10860, Minneapolis, MN 55440 Ph: (612) 262-1166 | Dr Simon Nicholas Fenton, MD 150 Emerson Ave E, Saint Paul, MN 55118-2535 Ph: (651) 241-1800 |
News Archive
Researchers from the US recently conducted a study to examine the clinical course and echocardiographic and lab testing across clinically defined fulminant and non-fulminant COVID-19 myocarditis. This study is published on the preprint server, medRxiv.*
Rapidly dividing cancer cells are skilled at patching up damage that would stop normal cells in their tracks, including wear and tear of telomeres, the protective caps at the end of each chromosome.
Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.
A new perspective article highlights a compelling theory about migraine attacks: that they are an integrated mechanism by which the brain protects and repairs itself. Recent insightful findings and potential ways to use them to help migraine sufferers are published in Headache.
› Verified 8 days ago
Huiying Guo, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 205 Wabasha St S, Saint Paul, MN 55107 Phone: 952-967-5584 | |
Sana Zekri, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 580 Rice St, Saint Paul, MN 55103 Phone: 651-982-7618 | |
David Alan Ness, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 721 Snelling Ave S, Saint Paul, MN 55116 Phone: 651-690-1311 Fax: 651-690-2447 | |
Patrick N Arnold, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 234 Wentworth Ave E, Saint Paul, MN 55118 Phone: 651-455-2940 Fax: 651-455-3354 | |
Laurel Ries, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 980 Rice St, Saint Paul, MN 55117 Phone: 651-326-9020 Fax: 651-326-9021 | |
Dr. Stephanie Dawnonnerate Stanton, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2500 Como Ave, Saint Paul, MN 55108 Phone: 952-853-8800 | |
Ravi Balasubrahmanyan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 333 Smith Ave N Ste 4640, Saint Paul, MN 55102 Phone: 651-241-1001 Fax: 651-241-1116 |